NCT00377481View on ClinicalTrials.gov

COMFORT Study: A Crossover Study of NeoRecormon (Epoetin Beta) and Darbepoetin Alfa in Patients With Renal Anemia.

PHASE4CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

September 30, 2006

Primary Completion Date

June 30, 2007

Study Completion Date

June 30, 2007

Conditions
Anemia
Interventions
DRUG

darbepoetin alfa

30 micrograms sc weekly (2 doses)

DRUG

epoetin beta [NeoRecormon]

6000 IU sc weekly (2 doses)

Trial Locations (8)

2065

St Leonards

2170

Liverpool

2250

Gosford

3052

Parkville

3168

Melbourne

4102

Woolloongabba

5011

Adelaide

NSW 2148

Sydney

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT00377481 - COMFORT Study: A Crossover Study of NeoRecormon (Epoetin Beta) and Darbepoetin Alfa in Patients With Renal Anemia. | Biotech Hunter | Biotech Hunter